SEARCH

SEARCH BY CITATION

REFERENCES

  • Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. 2005. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602603.
  • Baer R, Ludwig T. 2002. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 12:8691.
  • Becker TM, Rizos H, Kefford RF, Mann GJ. 2001. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin Cancer Res 7:32823288.
  • Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF, Mann GJ. 2005. Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun 332:873879.
  • Botuyan MV, Nomine Y, Yu X, Juranic N, Macura S, Chen J, Mer G. 2004. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure 12:11371146.
  • Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, Ohta T, Klevit R. 2003. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 100:56465651.
  • Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD. 1998. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1:421431.
  • Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN. 2007. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67:14941501.
  • Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. 2002. Autoubiquitination of the BRCA1*BARD1 RING ubiquitin ligase. J Biol Chem 277:2208522092.
  • Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, Smerdon SJ. 2004. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11:512518.
  • Coyne RS, McDonald HB, Edgemon K, Brody LC. 2004. Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay. Cancer Biol Ther 3:453457.
  • Daniels MJ, Wang Y, Lee M, Venkitaraman AR. 2004. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306:876879.
  • Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC. 2001. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7:273282.
  • Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G, Pierotti MA. 2001. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85:836844.
  • Drotschmann K, Clark AB, Kunkel TA. 1999a. Mutator phenotypes of common polymorphisms and missense mutations in MSH2. Curr Biol 9:907910.
  • Drotschmann K, Clark AB, Tran HT, Resnick MA, Gordenin DA, Kunkel TA. 1999b. Mutator phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. Proc Natl Acad Sci USA 96:29702975.
  • Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. 2007. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81:873883.
  • Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. 2008. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68:35233531.
  • Glover JN, Williams RS, Lee MS. 2004. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci 29:579585.
  • Goldgar DE, Easton DF, Byrnes GB, Spurdle AB, Iversen ES, Greenblatt MS, IARC Unclassified Genetic Variants Working Group. 2008. Integration of various data sources for classifying uncertain variants into a single model. Hum Mutat 29:12651272.
  • Goldstein AM. 2004. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23:630.
  • Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:98189828.
  • Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP. 2003. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 22:11501163.
  • Greenblatt MS, Brody LC, Foulkes W, Genuardi M, Hofstra R, Plon S, Sijmons RH, Sinilnikova OM, Spurdle AB; IARC Unclassified Genetic Variants Working Group. 2008. Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat 29:12731281.
  • Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. 2001. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 276:14537–11440.
  • Hayes F, Cayanan C, Barilla D, Monteiro AN. 2000. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res 60:24112418.
  • Heinen CD, Wilson T, Mazurek A, Berardini M, Butz C, Fishel R. 2002. HNPCC mutations in hMSH2 result in reduced hMSH2-hMSH6 molecular switch functions. Cancer Cell 1:469478.
  • Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. 2002. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606609.
  • Huang X, Shi Z, Wang W, Bai J, Chen Z, Xu J, Zhang D, Fu S. 2007. Identification and characterization of a novel protein ISOC2 that interacts with p16INK4a. Biochem Biophys Res Commun 361:287293.
  • Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD. 1997. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. Proc Natl Acad Sci USA 94:58205825.
  • Jager AC, Rasmussen M, Bisgaard HC, Singh KK, Nielsen FC, Rasmussen LJ. 2001. HNPCC mutations in the human DNA mismatch repair gene hMLH1 influence assembly of hMutLalpha and hMLH1-hEXO1 complexes. Oncogene 20:35903595.
  • Koh J, Enders GH, Dynlacht BD, Harlow E. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506510.
  • Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, Swaminathan S, van Buul PP, Errami A, Tan RT, Jaspers NG, Sharan SK, Kanaar R, Zdzienicka MZ. 2002. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 22:669679.
  • Kunkel TA, Erie DA. 2005. DNA mismatch repair. Annu Rev Biochem 74:681710.
  • Li GM. 2008. Mechanisms and functions of DNA mismatch repair. Cell Res 18:8598.
  • Longley MJ, Pierce AJ, Modrich P. 1997. DNA polymerase delta is required for human mismatch repair in vitro. J Biol Chem 272:1091710921.
  • Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. 1999. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 96:1136411369.
  • Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, Arnold S, Buchanan D; kConFab Investigators, Couch FJ, Henderson BR, Goldgar DE, Tavtigian SV, Chenevix-Trench G, Brown MA. 2007. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9:R82.
  • Marra G, D'Atri S, Yan H, Perrera C, Cannavo E, Vogelstein B, Jiricny J. 2001. Phenotypic analysis of hMSH2 mutations in mouse cells carrying human chromosomes. Cancer Res 61:77197721.
  • Monteiro AN, August A, Hanafusa H. 1996. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:1359513599.
  • Monteiro AN, August A, Hanafusa H. 1997. Common BRCA1 variants and transcriptional activation. Am J Hum Genet 61:761762.
  • Monteiro AN, Humphrey JS. 1998. Yeast-based assays for detection and characterization of mutations in BRCA1. Breast Dis 10:6170.
  • Monteiro AN. 2000. BRCA1: exploring the links to transcription. Trends Biochem Sci 25:469474.
  • Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. 1998. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879887.
  • Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. 2006. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet 15:599606.
  • Moynahan ME, Chiu JW, Koller BH, Jasin M. 1999. Brca1 controls homology-directed DNA repair. Mol Cell 4:511518.
  • Moynahan ME, Pierce AJ, Jasin M. 2001. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7:263272.
  • Nyström-Lahti M, Perrera C, Räschle M, Panyushkina-Seiler E, Marra G, Curci A, Quaresima B, Costanzo F, D'Urso M, Venuta S, Jiricny J. 2002. Functional analysis of MLH1 mutations linked to hereditary nonpolyposis colon cancer. Genes Chromosomes Cancer 33:160167.
  • Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F, Kohonen-Corish M, Gerdes AM, Peltomäki P, Mangold E, de la Chapelle A, Greenblatt M, Nyström M. 2006. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology 131:14081417.
  • Ou J, Niessen RC, Lutzen A, Sijmons RH, Kleibeuker JH, de Wind N, Rasmussen LJ, Hofstra RM. 2007. Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum Mutat 28:10471054.
  • Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. 1998. BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:23022306.
  • Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. 2000. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97:10201025.
  • Parry D, Peters G. 1996. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16:38443852.
  • Peltomaki P. 2001. DNA mismatch repair and cancer. Mutat Res 488:7785.
  • Peltomaki P. 2003. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21:11741179.
  • Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, kConFab, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN. 2005. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 42:138146.
  • Plon SE, Eccles DM, Easton DF, Foulkes W, Genuardi M, Greenblatt MS, Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian S; IARC Unclassified Genetic Variants Working Group. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29:xxx–yyy.
  • Polaczek P, Putzke AP, Leong K, Bitter GA. 1998. Functional genetic tests of DNA mismatch repair protein activity in Saccharomyces cerevisiae. Gene 213:159167.
  • Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lönnqvist KE, Holinski-Feder E, Sutter C, McKinnon W, Duraisamy S, Gerdes AM, Peltomäki P, Kohonen-Ccorish M, Mangold E, Macrae F, Greenblatt M, de la Chapelle A, Nyström M. 2005. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 129:537549.
  • Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. 1995. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114116.
  • Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF. 2001. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:4142441434.
  • Rodriguez M, Yu X, Chen J, Songyang Z. 2003. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains. J Biol Chem 278:5291452918.
  • Ruas M, Peters G. 1998. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115F177.
  • Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. 2001. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98:51345139.
  • Sacho EJ, Kadyrov FA, Modrich P, Kunkel TA, Erie DA. 2008. Direct visualization of asymmetric adenine-nucleotide-induced conformational changes in MutL alpha. Mol Cell 29:112121.
  • Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. 2008. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:11161120.
  • Sharpless NE. 2005. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576:2238.
  • Shcherbakova PV, Kunkel TA. 1999. Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations. Mol Cell Biol 19:31773183.
  • Soutoglou E, Misteli T. 2008. Activation of the cellular DNA damage response in the absence of DNA lesions. Science 320:15071510.
  • Spurdle AB, Couch FJ, Hogervorst FBL, Radice P, Sinilnikova OM; IARC Unclassified Genetic Variants Working Group. 2008. Prediction and assessment of splicing alterations. Hum Mutat 29:13041313.
  • Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, Schlegel BP, Gygi SP, Parvin JD. 2004. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. Mol Cell Biol 24:84578466.
  • Szabo CI, Worley T, Monteiro AN. 2004. Understanding germ-line mutations in BRCA1. Cancer Biol Ther 3:515520.
  • Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. 2007. Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays. Cancer Res 67:45954604.
  • Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. 2008a. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat 29:13421354.
  • Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB; IARC Unclassified Genetic Variants Working Group. 2008b. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29:13271336.
  • Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J, Plotz G, Jiricny J, Marra G. 2002. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology 122:211219.
  • Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A. 1999. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 9:11071110.
  • Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brøndum-Nielsen K, Gerdes AM, Møller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN. 2001. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353360.
  • Walker GJ, Gabrielli BG, Castellano M, Hayward NK. 1999. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer 82:305312.
  • Wang Q, Zhang H, Kajino K, Greene MI. 1998. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 17:19391948.
  • Williams RS, Glover JN. 2003. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem 278:26302635.
  • Williams RS, Chasman DI, Hau DD, Hui B, Lau AY, Glover JN. 2003. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 278:5300753016.
  • Williams RS, Lee MS, Hau DD, Glover JN. 2004. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 11:519525.
  • Worley T, Vallon-Christersson J, Billack B, Borg A, Monteiro AN. 2002. A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein. Cancer Biol Ther 1:497501.
  • Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. 2005. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65:417426.
  • Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. 2006. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22:719729.
  • Yang R, Gombart AF, Serrano M, Koeffler HP. 1995. Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 55:25032506.
  • Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee WH, Pavletich NP. 2002. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297:18371848.
  • Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. 1998. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 273:2538825392.
  • Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, West SC, Venkitaraman AR. 2000. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 14:14001406.
  • Zhang B, Peng Z. 1996. Defective folding of mutant p16(INK4) proteins encoded by tumor-derived alleles. J Biol Chem 271:2873428737.